Chemotherapy-induced polyneuropathy. Part I. Pathophysiology

Krzysztof Brzeziński, Krzysztof Brzeziński

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a toxic neuropathy, a syndrome consisting of highly distressing symptoms of various degrees of severity. It includes numbness of distal extremities, long-term touch, heat, and cold dysaesthesia and, in more severe cases, motor impairment affecting daily functioning. Each form of the syndrome may be accompanied by symptoms of neuropathic stinging, burning, and tingling pain. In the case of most chemotherapeutic agents, the incidence and severity of CIPN are dependent on the cumulative dose of the drug. The syndrome described is caused by damage to the axons and/or cells of the peripheral nervous system. Chemotherapeutic agents have distinct mechanisms of action in both neoplastic tissue and the peripheral nervous system; therefore, CIPN should not be regarded as a homogeneous disease entity. The present article is an attempt to systematize the knowledge about the toxic effects of chemotherapy on the peripheral nervous system.

Keywords: chemotherapy-induced polyneuropathy; neuropathic pain; pathophysiology; side effects.

References

    1. Ziółkowska E, Zarzycka M, Meller A, Wiśniewski T. Powikłania oczne po radioterapii nowotworów regionu głowy i szyi – przegląd piśmiennictwa. Wspolczesna Onkol. 2009;13:251–4.
    1. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109:132–42.
    1. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150–61.
    1. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122:245–57.
    1. Bennett GJ. Pathophysiology and animal models of cancer-related painful peripheral neuropathy. Oncologist. 2010;15:9–12.
    1. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. 2009;145:3–14.
    1. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripheral Nerv Syst. 2008;13:27–46.
    1. Ramirez JJ, Kaufmann SH, Windebank AJ. Paclitaxel potentiates cisplatin neurotoxicity in dorsal root ganglion neurons. Neurology. 1996;46:A288.
    1. Sun X, Windebank AJ. Hypoxia potentiates suramin neurotoxicity in rat dorsal root ganglia in vitro. Soc Neurosci. 1996;22:948. Abstr.
    1. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011;3:377–87.
    1. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–15.
    1. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64:1076–1077.
    1. Casanova-Molla J, Grau-Junyent JM, Morales M, Valls-Solé J. On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies. Pain. 2011;152:410–8.
    1. Gajos A, Kieliś W, Szadkowska I, Chmielowska E, Niewodniczy A, Bogucki A. Opis przypadku. Nabyte neuropatie obwodowe w przebiegu gammapatii monoklonalnych. Neurologia i Neurochirurgia Polska. 2007;41:169–75.
    1. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003;25:316–20.
    1. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996;77:1356–62.
    1. Bakshi N, Maselli RA, Gospe SM, Jr, Ellis WG, McDonald C, Mandler RN. Fulminant demyelinating neuropathy mimicking cerebral death. Muscle Nerve. 1997;20:1595–7.
    1. Orejana-García AM, Pascual-Huerta J, Pérez-Melero A. Charcot-Marie-Tooth disease and vincristine. J Am Podiatr Med Assoc. 2003;93:229–33.
    1. Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003;21:3761–9.
    1. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992;10:795–803.
    1. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer. 2000;82:966–72.
    1. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984;54:1269–75.
    1. Anzil AP, Blinzinger K, Herrlinger H. Fenestrated blood capillaries in rat cranio-spinal sensory ganglia. Cell Tissue Res. 1976;167:563–7.
    1. Jacobs JM. Vascular permeability and neurotoxicity. Environ Health Perspect. 1978;26:107–16.
    1. Olsson Y. Studies on vascular permeability in peripheral nerves. IV. Distribution of intravenously injected protein tracers in the peripheral nervous system of various species. Acta Neuropathol. 1971;17:114–26.
    1. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005;18:305–13.
    1. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27:992–1002.
    1. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101:2842–50.
    1. Podratz JL, Schlattau AW, Chen BK, Knight AM, Windebank AJ. Platinum adduct formation in mitochondrial DNA may underlie the phenomenon of coasting. J Peripher Nerv Syst. 2007;12:69.
    1. Eeles R, Tait DM, Peckham MJ. Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep. 1986;70:905–7.
    1. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 1993;116:1017–41.
    1. Fu KK, Kai EF, Leung CK. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J Clin Pharm Ther. 1995;20:167–72.
    1. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995;13:228–44.
    1. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985;3:246–50.
    1. Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982;39:719–20.
    1. Mollman JE, Hogan WM, Glover DJ, McCluskey LF. Unusual presentation of cis-platinum neuropathy. Neurology. 1988;38:488–90.
    1. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25:62–4.
    1. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729–35.
    1. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29:21–33.
    1. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.
    1. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003;30:5–13.
    1. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–92.
    1. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem. 2006;13:2901–7.
    1. Leonard GD, Wagner MR, Quinn MG, Grem JL. Severe disabling sensory-motor polyneuropathy during oxaliplatinbased chemotherapy. Anticancer Drugs. 2004;15:733–5.
    1. International Collaborative Ovarian NeoPlasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–15.
    1. Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry. 1997;63:133–6.
    1. Graus F, Keime-Guibert F, Reñé R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.
    1. Bryl M, Ramlau R, Dyszkiewicz W. Postępowanie w zaawansowanych inwazyjnych grasiczakach – przegląd piśmiennictwa. Wspolczesna Onkol. 2004;8:148–52.
    1. Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007:CD005228.
    1. Paulson JC, McClure WO. Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: an effect on microtubules. Ann N Y Acad Sci. 1975;253:517–27.
    1. Jackson DV, Jr, Castle MC, Poplack DG, Bender RA. Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates. Cancer Res. 1980;40:722–4.
    1. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol. 1990;26:263–8.
    1. Schaumburg H. Vinca Alkaloids. In: Schaumburg H, Spencer P, editors. Experimental and Clinical Neurotoxicology. 2nd ed. New York: Oxford University Press; 2000. pp. 1232–5.
    1. Pan YA, Misgeld T, Lichtman JW, Sanes JR. Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci. 2003;23:11479–88.
    1. Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80–4.
    1. Iqbal Z, Ochs S. Uptake of Vinca alkaloids into mammalian nerve and its subcellular components. J Neurochem. 1980;34:59–68.
    1. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study. Cancer Chemother Pharmacol. 1996;39:150–6.
    1. Burns BV, Shotton JC. Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol. 1998;112:485–7.
    1. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol. 1976;81:146–50.
    1. Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut. 1990;61:320–1.
    1. Kalcioglu MT, Kuku I, Kaya E, Oncel S, Aydogdu I. Bilateral hearing loss during vincristine therapy: a case report. J Chemother. 2003;15:290–2.
    1. Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve. 2003;27:646–61.
    1. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol. 1994;21:42–7.
    1. Curran MP, Plosker GL. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging. 2002;19:695–721.
    1. Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother. 2000;34:1136–8.
    1. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–9.
    1. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–51.
    1. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573–81.
    1. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14.
    1. Dzierzanowski T, Cialkowska-Rysz A. Neuropathic pain in palliative care patients. Medycyna Paliatywna. 2010;2:57–66.
    1. Apfel S. Taxoids. In: Schaumburg H, Spencer P, editors. Experimental and Clinical Neurotoxicology. 2nd ed. New York: Oxford University Press; 2000. pp. 1135–9.
    1. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489–94.
    1. Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropaty induced by docetaxel (Taxotere) Ann Oncol. 1997;8:187–90.
    1. Boillot A, Cordier A, Guerault E, Julliot MC, Balvay P, Billerey C, Barale F. A rare case of severe toxic peripheral neuropathy: poisoning by podophyllin. Apropos of 1 case. J Toxicol Clin Exp. 1989;9:409–12.
    1. Rogalska A, Marczak A, Szwed M, Gajek A, Jóźwiak Z. Epotilony – nadzieja dla pacjentów niewrażliwych na leczenie taksanami. Wspolczesna Onkol. 2010;14:205–10.
    1. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther. 1992;261:803–10.
    1. Bilińska M, Usnarska-Zubkiewicz L, Dmoszyńska A. Polineuropatia wywołana talidomidem i bortezomibem u chorych na szpiczaka mnogiego, możliwości leczenia bólu neuropatycznego. Zalecenia Polskiej Grupy Szpiczakowej. Wspolczesna Onkol. 2008;12:441–6.
    1. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies – dose-response and schedule dependence. J Clin Oncol. 1997;15:2378–84.
    1. Spivack SD. Drugs 5 years later: procarbazine. Ann Intern Med. 1974;81:795–800.
    1. Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep. 1977;61:885–7.
    1. Martín Algarra S, Henriquez I, Rebollo J, Artieda J. Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases. Anticancer Drugs. 1990;1:33–5.
    1. Cairncross G, Swinnen L, Bayer R, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000;2:114–9.
    1. Cho ES. Toxic effects of adriamycin on the ganglia of the peripherial nervous system: a neuropathological study. J Neuropathol Exp Neurol. 1977;36:907–15.
    1. Bigotte L, Olsson Y. Retrograde transport of doxorubicin (adriamycin) in peripheral nerves of mice. Neurosci Lett. 1982;32:217–21.
    1. Koh S, Nelson MD, Jr, Kovanlikaya A, Chen LS. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol. 1999;21:576–8.
    1. Moore BE, Somers NP, Smith TW. Methotrexate-related nonnecrotizing multifocal axonopathy detected by beta-amyloid precursor protein immunohistochemistry. Arch Pathol Lab Med. 2002;126:79–81.
    1. Boogerd W, Moffie D, Smets LA. Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer. 1990;65:452–7.
    1. Harila-Saari AH, Huuskonen UE, Tolonen U, Vainionpää LK, Lanning BM. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with moor evoked potentials. Med Pediatr Oncol. 2001;36:345–51.
    1. Ionasescu VV. Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve. 1995;18:267–75.
    1. Shibutani M, Okeda R, Hori A, Schipper H. Methotrexate-related multifocal axonopathy. Report of an autopsy case. Acta Neuropathol. 1989;79:333–5.
    1. Weiss S, Kahn Y. Intrathecal methotrexate causing paraplegia in a middle-aged woman. Acta Haematol. 1978;60:59–61.
    1. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. 1993;7:378–83.
    1. Russell JA, Powles RL. Letter: neuropathy due to cytosine arabinoside. Br Med J. 1974;4:652–3.
    1. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994;12:2216–28.
    1. Dormann AJ, Grünewald T, Wigginghaus B, Huchzermeyer H. Gemcitabine-associated autonomic neuropathy. Lancet. 1998;351:644.
    1. Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol. 2004;15:201–6.
    1. Allegra CJ, Grem JL. Antimetabolites. In: De Vita V, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice in Oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. pp. 432–52.
    1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.
    1. Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol. 1998;21:248–9.
    1. Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs. 2001;12:525–31.
    1. Hamilton S. Hand-foot syndrome. 2005. .
    1. Nagore E, Insa A, Sanmartín O. Antineoplastic therapyinduced palmar plantar erythrodysesthesia (“hand-foot”) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225–34.
    1. Russell JW, Gill JS, Sorenson EJ, Schultz DA, Windebank AJ. Suramin-induced neuropathy in an animal model. J Neurol Sci. 2001;192:71–80.
    1. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119:2039–52.
    1. Hussein MA. Lenalidomide: patient management strategies. Semin Hematol. 2005;42:22–5.
    1. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729–35.
    1. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:1741–6.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa